hers oral tirzepatide Hims & Expands Weight Loss Offering, Adds Lilly's Zepbound to Platform Compounded Oral Tirzepatide Tablets –

Mankind Pharma reported FY26 revenue of 14,278 Cr (+17% YoY) with adjusted EBITDA margins of 25.4%

Clinical studies have shown that patients who reach and maintain their target dose typically achieve 15-20% greater weight loss compared to those who remain at lower doses

02/16/2026 Electronic publication Footnotes Conflict of interest: RJJ has received grant support from the Royal Australasian College of Physicians and Australian Diabetes Society

We take time to understand your health history, goals, lifestyle, body composition, lab markers, and any factors that may be affecting your ability to lose weight

PMID: 21795440 Watanabe F, et al